

Monoclonal Antibodies Detecting Human Antigens



PAC-1

Form	Catalog number
Pure	340535
FITC	340507

Product availability varies by region. Contact BD Biosciences Customer Support or your local sales representative for information.

RESEARCH APPLICATIONS

Research applications include studies of:

- Hemostasis and thrombosis in clinical disorders and vascular injury¹⁻⁴
- Metabolic reactions responsible for platelet surface changes^{1,2,5-8}
- Structure and functions of gpIIb/IIIa and its adhesive ligands^{5,7,9,10}
- Therapeutic strategies to prevent platelet activation^{1,2,3,4,11}

DESCRIPTION

Specificity

The PAC-1 antibody recognizes an epitope on the glycoprotein IIb/IIIa (gpIIb/IIIa, $\alpha_{IIb}\beta_3$) complex of activated platelets at or near the platelet fibrinogen receptor.^{1,2,9,12-15}

Antigen distribution

The gpIIb/IIIa complex is a member of a family of heterodimeric adhesive protein receptors found on a variety of cell types that have been named the integrin or the cytoadhesion family.^{11,15-16}

The gpIIb/IIIa complex is located on the surface membrane of resting platelets.³ Platelet activation induces a calcium-dependent conformational change in gpIIb/IIIa that exposes a ligand binding site.^{3,11,14,16} Four adhesive macromolecules are capable of interacting with the activated form of gpIIb/IIIa: fibrinogen, von Willebrand factor (vWf), fibronectin, and vitronectin.^{3,6,10,11,15} The binding of fibrinogen to the gpIIb/IIIa receptor is required for platelet aggregation.^{1,9,11,14,16} PAC-1 binds only to activated platelets and appears to be specific for this recognition site within gpIIb/IIIa.^{4,9-11} Approximately 45,000 to 50,000 gpIIb/IIIa receptors appear on the platelet surface upon activation.^{3,14} PAC-1 inhibits fibrinogen-mediated platelet aggregation.^{11,14}

Clone

The PAC-1 antibody is derived from the fusion of SP-2 mouse myeloma cells with splenic lymphocytes from BALB/c mice that were immunized with human platelets.^{11,14}

Composition

The PAC-1 antibody is a pentameric IgM κ -immunoglobulin.^{1,3,4,9,14}

Product configuration

The following are supplied in phosphate buffered saline (PBS) containing a stabilizer and a preservative.

Form	Number of tests	Volume per test (μ L) ^a	Amount provided (μ g)	Total volume (mL)	Concentration (μ g/mL)	Stabilizer	Preservative
Pure	N/A	N/A	200	0.2	1,000	N/A	0.01% Sodium azide
FITC	50	20	25	1.0	25	Gelatin	0.1% Sodium azide

a. Volume required to stain 10^6 cells.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Becton, Dickinson and Company
BD Biosciences
2350 Qume Drive
San Jose, CA 95131 USA



PROCEDURE


Visit our website (bdbiosciences.com) or contact your local BD representative for the lyse/wash protocol for direct immunofluorescence.

Activation-dependent antibody binding can be affected by fixation and choice of anticoagulant. PAC-1 will not bind fixed platelets or EDTA-treated blood. For details on preparation and staining of platelets, see the Becton Dickinson procedure, Three-Color Analysis of Platelet Activation, *Monoclonal Antibodies Source Book*, Section 2.25.

REPRESENTATIVE DATA

Flow cytometric analysis was performed on ADP-activated platelets with an FL3 threshold gate set on CD61 PerCP (positive events). Specificity of PAC-1 binding is demonstrated by staining in the presence of RGDS peptide, a competitive inhibitor.¹⁵ Laser excitation is at 488 nm. Representative data analyzed with a BD FACS™ brand flow cytometer is shown in the following plots.

Figure 1 Two-parameter displays of platelets analyzed with a BD FACS™ brand flow cytometer



HANDLING AND STORAGE

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed. Please refer to the vial label for antibody concentration.

WARNING

All biological specimens and materials coming in contact with them are considered biohazards. Handle as if capable of transmitting infection^{17,18} and dispose of with proper precautions in accordance with federal, state, and local regulations. Never pipette by mouth. Wear suitable protective clothing, eyewear, and gloves.

CHARACTERIZATION

To ensure consistently high-quality reagents, each lot of antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

WARRANTY

Unless otherwise indicated in any applicable BD general conditions of sale for non-US customers, the following warranty applies to the purchase of these products.

THE PRODUCTS SOLD HEREUNDER ARE WARRANTED ONLY TO CONFORM TO THE QUANTITY AND CONTENTS STATED ON THE LABEL OR IN THE PRODUCT LABELING AT THE TIME OF DELIVERY TO THE CUSTOMER. BD DISCLAIMS HEREBY ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE AND NONINFRINGEMENT. BD'S SOLE LIABILITY IS LIMITED TO EITHER REPLACEMENT OF THE PRODUCTS OR REFUND OF THE PURCHASE PRICE. BD IS NOT LIABLE FOR PROPERTY DAMAGE OR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING PERSONAL INJURY, OR ECONOMIC LOSS, CAUSED BY THE PRODUCT.

REFERENCES

1. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. *Blood*. 1987;70:307-315.
2. Abrams CS, Ellison N, Budzinski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. *Blood*. 1990;75:128-138.
3. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. *Thrombosis and Haemostasis*. 1991;65:467-473.
4. Michelson AD. Flow cytometry: A clinical test of platelet function. *Blood*. 1996;87:4925-4936.
5. Shattil SJ, Cunningham M, Wiedmer T, et al. Regulation of glycoprotein IIb-IIIa receptor function studied with platelets permeabilized by the pore-forming complement proteins C5b-9. *J Biol Chem*. 1992;267:18424-18431.
6. Huang M-M, Lipfert L, Cunningham M, et al. Adhesive ligand binding to integrin $\alpha_{IIb}\beta_3$ stimulates tyrosine phosphorylation of novel protein substrates before phosphorylation of pp125^{FAK}. *J Cell Biol*. 1993;122:473-483.
7. O'Toole TE, Mandelman D, Forsyth J, et al. Modulation of the affinity of integrin $\alpha_{IIb}\beta_3$ (GPIIb-IIIa) by the cytoplasmic domain of α_{IIb} . *Science*. 1991;254:845-847.
8. Abrams C, Deng Y-J, Steiner B, O'Toole T, Shattil SJ. Determinants of specificity of a baculovirus-expressed antibody Fab fragment that binds selectively to the activated form of integrin $\alpha_{IIb}\beta_3$. *J Biol Chem*. 1994;269:18781-18788.
9. Taub R, Gould RJ, Garsky VM, et al. A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen. *J Biol Chem*. 1989;264:259-265.
10. Abrams CS, Ruggeri ZM, Taub R, et al. Anti-idiotypic antibodies against an antibody to the platelet glycoprotein (GP) IIb-IIIa complex mimic GP IIb-IIIa by recognizing fibrinogen. *J Biol Chem*. 1992;267:2775-2785.
11. Shattil SJ, Weisel JW, Kieber-Emmons T. Use of monoclonal antibodies to study the interaction between an integrin adhesion receptor, GP IIb-IIIa, and its physiological ligand, fibrinogen. *Immunomethods*. 1993;1:53-63.
12. Springer TA. Adhesion receptors of the immune system. *Nature*. 1990;346:425-434.
13. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. *Cell*. 1992;69:11-25.
14. Shattil SJ, Hoxie JA, Cunningham M, Brass L. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. *J Biol Chem*. 1985;260:11107-11114.
15. Bennett JS, Shattil SJ, Power JW, Gartner TK. Interaction of fibrinogen with its platelet receptor. *J Biol Chem*. 1988;263:12948-12953.
16. Ginsberg MH, Frelinger AL, Lam S, et al. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. *Blood*. 1990;76:2017-2023.
17. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline — Third Edition*. Wayne, PA: Clinical and Laboratory Standards Institute; 2005. CLSI document M29-A3.
18. Centers for Disease Control. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR*. 1988;37:377-388.

PATENTS AND TRADEMARKS

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2015 BD